Voriconazole-Induced QT Interval Prolongation: A Prospective Study
Status
Conditions
Details and patient eligibility
About
The antifungal voriconazole is effective for the treatment of invasive fungal infections in immunocompromised patients. A serious adverse reaction is QT interval prolongation, which may precede life-threatening arrhythmias, such as torsades de pointes. Although ventricular arrhythmias are mentioned as a possible adverse effect of voriconazole, thus far, the incidence and clear recommendations for QT follow-up have not been published. This prospective observational study aimed at describing the incidence of voriconazole induced- QT interval prolongation in the pediatric population and determine the risk factors for this phenomenon.
Enrollment
Sex
Ages
Volunteers
Inclusion criteria
- oral or IV treatment with voriconazole
Exclusion criteria
- No data prior to initiation of voriconazole treatment on QT interval (baseline ECG)
- Renal insufficiency or dialysis treatment
Trial contacts and locations
Loading...
Data sourced from clinicaltrials.gov
Clinical trials
Research sites
Resources
Legal